PD-1 AND PD-L1 INHIBITOR MARKET ANALYSIS

PD-1 and PD-L1 Inhibitor Market, By Type of Inhibitor (PD-1 Inhibitors, PD-L1 Inhibitors), By Cancer Type (Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Mar 2024
Code : CMI173
Pages :169
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Concentration and Competitive Landscape

PD-1 and PD-L1 Inhibitor Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Growing geriatric population

Growing geriatric population around the world is expected to augment growth of the global PD-1 and PD-L1 inhibitor market during the forecast period. For instance, according to the Union for International Cancer Control (UICC), elderly (people aged 65 years and more) are 11 times more likely to develop cancer, compared to younger people. According to the United Nations January 2023 press release, there are over 761 million people aged 65 or older in 2021, a number that is projected to reach 1.6 billion by 2050.

Key Players Insights